Pyridoxamine Derivatives Inhibit AGE ALE Formation
Solution Overview
Problem
There is a need for additional treatment options to inhibit the development of advanced glycation end-products (AGE) and advanced lipoxidation end-products (ALE) associated complications, particularly in patients with hyperglycemia and/or hyperlipidemia, as current therapies are limited in effectively addressing these conditions.
Innovation Solution
The development of novel compounds and pharmaceutical compositions that inhibit the formation of AGEs and ALEs, which are administered to subjects suffering from hyperglycemia and/or hyperlipidemia to treat or prevent complications such as diabetic nephropathy, atherosclerosis, and dialysis-related disorders, by interfering with the oxidative breakdown of Amadori intermediates and binding with redox metal ions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat hyperglycemia and hyperlipidemia, then existing treatment options are available, but they are limited in effectively addressing AGE and ALE associated complications
Solution Approach 1:
The patent segments the therapeutic approach by developing distinct compounds with specific molecular structures (formula I) that selectively inhibit AGE and ALE formation pathways. This segmentation provides specialized treatment options for different complications rather than using broad-spectrum therapies.
Solution Approach 2:
The patent employs composite molecular structures combining pyridoxamine derivatives with specific substituents (formula I) to create compounds that simultaneously address multiple pathogenic mechanisms including glycation, lipoxidation, and oxidative stress, thereby providing versatile treatment for various complications.
2Reliability
If pyridoxamine is used to inhibit AGE and ALE formation, then it shows therapeutic benefit in animal models, but further treatment options are needed
Solution Approach 1:
The patent modifies the molecular parameters of pyridoxamine by introducing various substituents at specific positions (R1-R6, G, X, Y, Z) to optimize binding affinity and selectivity for AGE/ALE inhibition while reducing off-target effects, thereby expanding the therapeutic toolkit beyond plain pyridoxamine.
Solution Approach 2:
The patent applies local quality modifications by placing specific functional groups at particular positions on the molecular scaffold (e.g., heterocyclic groups at G position, alkyl chains at R positions) to enhance specific interactions with target proteins involved in AGE/ALE formation pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the formation of AGEs and ALEs, reducing the progression of associated complications like diabetic nephropathy and atherosclerosis, and demonstrate improved safety and efficacy compared to existing treatments, with enhanced binding affinity for metal ions and reduced toxicity.
Implementation Method 1
binding with redox metal ions
Data Source
AI summary
The present invention provides compounds of the formula,wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.